(Q38203306)

30 August 2017

title

Postoperative therapy options for hepatocellular carcinoma (English)

1 reference

30 August 2017

Jian-Hong Zhong

1

0 references

author name string

Liang Ma

series ordinal

2

1 reference

30 August 2017

Le-Qun Li

series ordinal

3

1 reference

30 August 2017

publication date

10 April 2014

1 reference

Scandinavian Journal of Gastroenterology

30 August 2017

published in

1 reference

30 August 2017

volume

49

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

649-661

1 reference

30 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Null genotype of glutathione S-transferase Tl contributes to colorectal cancer risk in the Asian population: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Oral supplementation with carbohydrate- and branched-chain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Development of heparanase inhibitors for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Meta-analysis of microsomal epoxide hydrolase gene polymorphism and risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.905626

10.3109/00365521.2014.905626

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference